Congress Last Resort On IPRs After Supreme Court Backs Patent Board

Biopharmaceutical industry lobbying efforts are expected to jump into overdrive on Capitol Hill to get Congress to ban the use of the broadest reasonable interpretation by the US Patent & Trademark Office Patent Trial and Appeal Board after the Supreme Court backed the standard for conducting inter partes reviews – trial proceedings created five years ago to be a faster and more affordable alternative to challenging patents in the courts.